Adial Pharmaceuticals, Inc. Issues Restricted Stock Awards to Key Executives

Key Points

• Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) filed a Form 8-K with the SEC, dated April 7, 2026, reporting the issuance of Restricted Stock Awards (RSAs) to two of its top executives under the Company’s 2017 Equity Incentive Plan.
• The RSAs were granted to Chief Financial Officer Vinay Shah and Chief Operating Officer/Director Tony Goodman.
• The awards are intended as part of the executives’ compensation and are subject to the terms of the plan and restricted stock award agreements.

Details of the Restricted Stock Awards

• Vinay Shah (Chief Financial Officer): Granted 17,325 RSAs, all of which were issued to him for his service as CFO.
• Tony Goodman (Chief Operating Officer and Director): Awarded a total of 26,510 RSAs, with 17,325 for his role as COO and an additional 9,185 RSAs for his service as a Director of the Company.
• The RSAs are governed by the Company’s 2017 Equity Incentive Plan, and the specific terms and restrictions are outlined in a Form of Restricted Stock Award Agreement, which was also filed as an exhibit to the 8-K.

Implications for Shareholders

• Potential Share Dilution: The issuance of new shares to executives could have a dilutive effect on existing shareholders. However, such grants are a common method of aligning the interests of management and shareholders by incentivizing performance and retention.
• Governance and Transparency: The awards were disclosed in line with SEC requirements, demonstrating transparency in the company’s executive compensation practices.
• Price Sensitivity: While executive compensation via equity is standard for companies at Adial’s stage, the potential dilution and the company’s ability to retain key personnel may influence investor sentiment and, therefore, the share price.
• Plan Details: The RSAs are subject to vesting, transfer restrictions, potential forfeiture, and other conditions as per the agreement. The document also outlines the executives’ rights as shareholders (including voting and dividend rights once restrictions lapse), tax considerations (including Section 83(b) elections), and company recoupment rights under regulatory requirements.

Additional Information

• The company’s common stock trades on the Nasdaq Capital Market under the symbol ADIL.
• As of the report date, Adial Pharmaceuticals does not qualify as an “emerging growth company” under the SEC’s definitions, which may impact its compliance obligations and disclosure requirements.
• The company’s fiscal year ends on December 31.

Exhibits Filed

• Exhibit 10.1: Form of Restricted Stock Award Agreement under the 2017 Equity Incentive Plan (details the terms, restrictions, and rights associated with the RSAs).
• Exhibit 104: Cover Page Interactive Data File (Inline XBRL).

Summary for Investors

The granting of restricted stock awards to Adial Pharmaceuticals’ CFO and COO/Director is a noteworthy governance and compensation event. While the direct financial impact may be limited, shareholders should be aware of the potential for dilution and the alignment of executive and shareholder interests. The transparency of these awards and their terms is a positive for corporate governance. Investors may wish to monitor further disclosures regarding the vesting and performance of these awards, as well as any additional equity grants or changes in executive compensation policy.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult with a qualified financial advisor before making investment decisions. The information herein is based on public SEC filings and may not reflect all current or future developments at Adial Pharmaceuticals, Inc.

View ADIAL PHARMACEUTICALS, INC. Historical chart here